Clemens H M Kocken

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4686023/publications.pdf

Version: 2024-02-01

40 papers	2,318 citations	361413 20 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	3229 citing authors

#	Article	IF	Citations
1	Metabolic, Pharmacokinetic, and Activity Profile of the Liver Stage Antimalarial (RC-12). ACS Omega, 2022, 7, 12401-12411.	3.5	1
2	A Bacterially-Expressed Recombinant Envelope Protein from Usutu Virus Induces Neutralizing Antibodies in Rabbits. Vaccines, 2021, 9, 157.	4.4	3
3	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Reports Medicine, 2021, 2, 100187.	6.5	26
4	A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation. Communications Biology, 2020, 3, 7.	4.4	36
5	Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines, 2020, 8, 363.	4.4	7
6	Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization. Science Translational Medicine, 2020, 12, .	12.4	33
7	Dual-Luciferase-Based Fast and Sensitive Detection of Malaria Hypnozoites for the Discovery of Antirelapse Compounds. Analytical Chemistry, 2020, 92, 6667-6675.	6.5	7
8	Modeling Relapsing Malaria: Emerging Technologies to Study Parasite-Host Interactions in the Liver. Frontiers in Cellular and Infection Microbiology, 2020, 10, 606033.	3.9	11
9	Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malarias Plasmodium vivax and Plasmodium ovale Infections in Non-Human Primates. Frontiers in Cellular and Infection Microbiology, 2020, 10, 614122.	3.9	9
10	Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. Nature Communications, 2019, 10, 3635.	12.8	39
11	Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits. BMC Immunology, 2019, 20, 25.	2.2	4
12	From marginal to essential: the golden thread between nutrient sensing, medium composition and Plasmodium vivax maturation in in vitro culture. Malaria Journal, 2019, 18, 344.	2.3	17
13	Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nature Medicine, 2019, 25, 255-262.	30.7	227
14	Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity. Frontiers in Immunology, 2019, 10, 2479.	4.8	27
15	Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation. BMC Immunology, 2018, 19, 6.	2.2	8
16	Plasmodium knowlesi: a relevant, versatile experimental malaria model. Parasitology, 2018, 145, 56-70.	1.5	23
17	Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails. Tuberculosis, 2017, 104, 46-57.	1.9	80
18	Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Science Translational Medicine, 2017, 9, .	12.4	204

#	Article	IF	Citations
19	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	12.8	51
20	A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi. ELife, 2017, 6, .	6.0	56
21	Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. PLoS ONE, 2017, 12, e0185303.	2.5	17
22	PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrobial Agents and Chemotherapy, 2016, 60, 2858-2863.	3.2	45
23	High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infectious Diseases, 2016, 2, 281-293.	3.8	84
24	Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation. PLoS ONE, 2016, 11, e0164053.	2.5	7
25	Low Levels of Polymorphisms and No Evidence for Diversifying Selection on the Plasmodium knowlesi Apical Membrane Antigen 1 Gene. PLoS ONE, 2015, 10, e0124400.	2.5	15
26	Workshop report: Malaria vaccine development in Europeâ€“preparing for the future. Vaccine, 2015, 33, 6137-6144.	3.8	15
27	Crystal Structure of Plasmodium knowlesi Apical Membrane Antigen 1 and Its Complex with an Invasion-Inhibitory Monoclonal Antibody. PLoS ONE, 2015, 10, e0123567.	2.5	16
28	Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nature Medicine, 2014, 20, 307-312.	30.7	160
29	Lead Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on Plasmodium Liver Stages. ACS Medicinal Chemistry Letters, 2014, 5, 947-950.	2.8	30
30	Antibody Responses to a Novel Plasmodium falciparum Merozoite Surface Protein Vaccine Correlate with Protection against Experimental Malaria Infection in Aotus Monkeys. PLoS ONE, 2014, 9, e83704.	2.5	10
31	Targeting Plasmodium PI(4)K to eliminate malaria. Nature, 2013, 504, 248-253.	27.8	377
32	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Science Translational Medicine, 2013, 5, 177ra37.	12.4	187
33	Statistical Model To Evaluate In Vivo Activities of Antimalarial Drugs in a Plasmodium cynomolgi -Macaque Model for Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2009, 53, 421-427.	3.2	10
34	Transgenic Plasmodium knowlesi: relieving a bottleneck in malaria research?. Trends in Parasitology, 2009, 25, 370-374.	3.3	16
35	A Diversity-Covering Approach to Immunization with Plasmodium falciparum Apical Membrane Antigen 1 Induces Broader Allelic Recognition and Growth Inhibition Responses in Rabbits. Infection and Immunity, 2008, 76, 2660-2670.	2.2	107
36	Plasmodium vivax: In vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. Experimental Parasitology, 2006, 113, 197-200.	1.2	22

#	Article	IF	Citations
37	High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion. Infection and Immunity, 2002, 70, 4471-4476.	2.2	181
38	Plasmodium knowlesi Provides a Rapid In Vitro and In Vivo Transfection System That Enables Double-Crossover Gene Knockout Studies. Infection and Immunity, 2002, 70, 655-660.	2.2	81
39	Transformed Toxoplasma gondiiTachyzoites Expressing the Circumsporozoite Protein ofPlasmodium knowlesi Elicit a Specific Immune Response in Rhesus Monkeys. Infection and Immunity, 1999, 67, 1677-1682.	2.2	6
40	Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. European Journal of Immunology, 1998, 28, 1225-1232.	2.9	53